Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Gardasil sBLA Gets Priority Review In Older Women

This article was originally published in The Pink Sheet Daily

Executive Summary

Company seeks approval of the vaccine for women ages 27 through 45.

You may also be interested in...



Novavax CEO Rahul Singhvi - An Interview With “The Pink Sheet” DAILY

Vaccine firm tells "The Pink Sheet" DAILY about its virus-like particles process for making vaccines and how its processes can be less expensive and require smaller facilities.

Novavax CEO Rahul Singhvi - An Interview With “The Pink Sheet” DAILY

Vaccine firm tells "The Pink Sheet" DAILY about its virus-like particles process for making vaccines and how its processes can be less expensive and require smaller facilities.

Merck Receives FDA “Complete Response” On Gardasil For Women 27-45

Firm also receives complete response to its sBLA for cross-protection.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067437

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel